Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Heart Failure

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44346   clinical trials with a EudraCT protocol, of which   7374   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    Query did not match any clinical trials.
    These are paediatric studies completed by 26 January 2007, in respect of products authorised in the Community (Article 45 of the Paediatric Regulation (EC) No 1901/2006).
    Note: Advanced search filters for country, trial phase, gender, rare disease, IMP with orphan designation in the indication and age ranges of in-utero, adult or elderly do not apply to these records.
    Study title: "Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meat-analysis of individual data from 6500 patients in randomised trials. - ATMA investigators. - 1997 (Lancet, 350: 1417-1424) ; - Publicati" "Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meat-analysis of individual data from 6500 patients in randomised trials. - ATMA investigators. - 1997 (Lancet, 350: 1417-1424) ; - Publicati"
    Active substance: AMIODARONE
    Study summary document link (including results):
    View full study record
    Document reference: 45201
    Study title: Bumetanide in heart failure in infancy. O C Ward and L K T Lam. Arch. Dis. Child, 1977; 52: 877-882Bumetanide in heart failure in infancy. O C Ward and L K T Lam. Arch. Dis. Child, 1977; 52: 877-882
    Active substance: BUMETANIDE OR BUMETANIDE AND FORMOTEROL
    Study summary document link (including results):
    View full study record
    Document reference: 23059
    Study title: McBride, M.G., T.J. Binder, and S.M. Paridon, Safety and feasibility of inpatient exercise training in pediatric heart failure: a preliminary report. J Cardiopulm Rehabil Prev, 2007. 27(4): p. 219-22. 4. McBride, M.G., T.J. Binder, and S.M. Paridon, Safety and feasibility of inpatient exercise training in pediatric heart failure: a preliminary report. J Cardiopulm Rehabil Prev, 2007. 27(4): p. 219-22. 4.
    Active substance: DOBUTAMINE
    Study summary document link (including results):
    View full study record
    Document reference: 26287
    Study title: Comparison of the therapeutic effects of the beta−blocking agent bisoprolol and the calcium−blocking agent diltiazem in patients with heart failure due to dilated cardiomyopathy. Suwa M, Ito T, Otake Y, Moriguchi A, Hirota Y, Kawamura K. Japanese circulation journal, Oct 1996, vol. 60, no. 10, p. 767−73Comparison of the therapeutic effects of the beta−blocking agent bisoprolol and the calcium−blocking agent diltiazem in patients with heart failure due to dilated cardiomyopathy. Suwa M, Ito T, Otake Y, Moriguchi A, Hirota Y, Kawamura K. Japanese circulation journal, Oct 1996, vol. 60, no. 10, p. 767−73
    Active substance: DILTIAZEM
    Study summary document link (including results):
    View full study record
    Document reference: 26126
    Study title: Closure of the arterial canal induced by indometacin in premature neonates with severe congestive heart failure
    Active substance: INDOMETHACIN
    Study summary document link (including results):
    View full study record
    Document reference: 29837
    Study title: Efficacy and safety of Primacor in pediatric patients with congestive heart failure following cardiac surgery. Efficacy and safety of Primacor in pediatric patients with congestive heart failure following cardiac surgery. 
    Active substance: MILRINONE
    Study summary document link (including results):
    View full study record
    Document reference: 32023
    Study title: "Reversed vVntilation Perfusion Mismatch Involving a pediatric Patient in Congestive Heart Failure - Evan Zucker, Sydney Heyman and Savas Ozdemir - The Journal of Nuclear Medicine Vol 38 - No 11- November 1997" "Reversed vVntilation Perfusion Mismatch Involving a pediatric Patient in Congestive Heart Failure - Evan Zucker, Sydney Heyman and Savas Ozdemir - The Journal of Nuclear Medicine Vol 38 - No 11- November 1997"
    Active substance: MILRINONE
    Study summary document link (including results):
    View full study record
    Document reference: 32037
    Study title: Reversed ventilation-perfusion mismatch involving a pediatric patient in congestive heart failure. Zucker I, Heyman S, Ozdemir S. J Nucl Med. 1997 Nov;38(11):1681-3.
    Active substance: TECHNETIUM (99m)
    Study summary document link (including results): Zucker I 1997.pdf
    View full study record
    Document reference: 48245
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Jun 27 22:19:15 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA